- Home
- GRAF vs CRBU Comparison
GRAF vs CRBU Comparison
Compare GRAF & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAF
- CRBU
- Stock Information
- Founded
- GRAF 2021
- CRBU 2011
- Country
- GRAF United States
- CRBU United States
- Employees
- GRAF N/A
- CRBU N/A
- Industry
- GRAF
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- GRAF
- CRBU Health Care
- Exchange
- GRAF NYSE
- CRBU Nasdaq
- Market Cap
- GRAF 288.9M
- CRBU 236.3M
- IPO Year
- GRAF 2024
- CRBU 2021
- Fundamental
- Price
- GRAF $10.08
- CRBU $1.79
- Analyst Decision
- GRAF
- CRBU Strong Buy
- Analyst Count
- GRAF 0
- CRBU 4
- Target Price
- GRAF N/A
- CRBU $12.00
- AVG Volume (30 Days)
- GRAF 41.2K
- CRBU 1.5M
- Earning Date
- GRAF 01-01-0001
- CRBU 11-06-2024
- Dividend Yield
- GRAF N/A
- CRBU N/A
- EPS Growth
- GRAF N/A
- CRBU N/A
- EPS
- GRAF 0.25
- CRBU N/A
- Revenue
- GRAF N/A
- CRBU $11,475,000.00
- Revenue This Year
- GRAF N/A
- CRBU N/A
- Revenue Next Year
- GRAF N/A
- CRBU N/A
- P/E Ratio
- GRAF $40.59
- CRBU N/A
- Revenue Growth
- GRAF N/A
- CRBU N/A
- 52 Week Low
- GRAF $9.03
- CRBU $1.50
- 52 Week High
- GRAF $11.02
- CRBU $8.33
- Technical
- Relative Strength Index (RSI)
- GRAF N/A
- CRBU 37.96
- Support Level
- GRAF N/A
- CRBU $1.72
- Resistance Level
- GRAF N/A
- CRBU $1.97
- Average True Range (ATR)
- GRAF 0.00
- CRBU 0.14
- MACD
- GRAF 0.00
- CRBU -0.03
- Stochastic Oscillator
- GRAF 0.00
- CRBU 9.12
About GRAF GRAF GLOBAL CORP
Graf Global Corp is a blank check company.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.